ES2106616T3 - Derivados de 11,21-bisfenilo-19-nor-pregnanos. - Google Patents
Derivados de 11,21-bisfenilo-19-nor-pregnanos.Info
- Publication number
- ES2106616T3 ES2106616T3 ES95201268T ES95201268T ES2106616T3 ES 2106616 T3 ES2106616 T3 ES 2106616T3 ES 95201268 T ES95201268 T ES 95201268T ES 95201268 T ES95201268 T ES 95201268T ES 2106616 T3 ES2106616 T3 ES 2106616T3
- Authority
- ES
- Spain
- Prior art keywords
- nr5r6
- alkyl
- bisphenyl
- son
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Seasonings (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
LA INVENCION SE REFIERE A UN DERIVADO DEL 11,21-BISFENIL-19NORPREGNANO DE LA FORMULA (I) EN DONDE R{SUB, 1} SE SELECCIONA ENTRE H, HALOGENO, ALCOXIDO C{SUB, 1-6), Y NR{SUB, 5}R{SUB, 6}, R{SUB, 5} Y R{SUB, 6} SON INDEPENDIENTEMENTE HIDROGENO O ALQUIL C{SUB, 1-6} O R{SUB, 5} Y R{SUB, 6} JUNTAS SON ALQUILENO C{SUB, 3-6}; R{SUB, 2} ES HIDROGENO; O R{SUB, 1} Y R{SUB, 2} JUNTAS SON UN GRUPO DE ALQUILENODIOXIDO C{SUB, 1-3}, OPCIONALMENTE SUSTITUIDO POR UNO O MAS ATOMOS DE HALOGENO; R{SUB, 3} ES METIL O ETIL; R{SUB, 4} SE SELECCIONA ENTRE C(O)-NR{SUB, 5}R{SUB, 6}, SO{SUB, N}-ALQUIL (C{SUB, 1-6} SUSTITUIDO POR UNO O MAS ATOMOS DE HALOGENO; SO{SUB, N}CICLOALQUIL C{SUB, 3-6}, N ES 1 O 2, SO{SUB, 2}-N{SUB, 5}R{SUB, 6}, 2-OXYPIRROLIDINIL, Y NR{SUB, 5}R{SUB, 6}; R{SUB, 7} ES H O ALQUIL C{1-6}, R{SUB, 8} ES H O CARBOXI-1-OXO-ALQUIL C{SUB, 1-6}; Y X SE SELECCIONA ENTRE (H, OH), O, Y NOH; 11. TAMBIEN SE PRESENTAN LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS MISMOS. LOS COMPUESTOS DE LA INVENCION TIENEN ACTIVIDAD ANTI-GLUCOCORTICOIDE Y PUEDEN UTILIZARSE EN EL TRATAMIENTO O LA PREVENCION DE ENFERMEDADES DEPENDIENTES DE LOS GLUCOCORTICOIDES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94201431 | 1994-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2106616T3 true ES2106616T3 (es) | 1997-11-01 |
Family
ID=8216894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95201268T Expired - Lifetime ES2106616T3 (es) | 1994-05-19 | 1995-05-16 | Derivados de 11,21-bisfenilo-19-nor-pregnanos. |
Country Status (20)
Country | Link |
---|---|
US (1) | US5620966A (es) |
EP (1) | EP0683172B1 (es) |
JP (1) | JP3814312B2 (es) |
KR (1) | KR100359474B1 (es) |
CN (1) | CN1042539C (es) |
AT (1) | ATE156836T1 (es) |
AU (1) | AU701616B2 (es) |
BR (1) | BR9502085A (es) |
CA (1) | CA2149496C (es) |
DE (1) | DE69500542T2 (es) |
DK (1) | DK0683172T3 (es) |
ES (1) | ES2106616T3 (es) |
FI (1) | FI112491B (es) |
GR (1) | GR3025225T3 (es) |
HU (1) | HU217429B (es) |
NO (1) | NO304379B1 (es) |
NZ (1) | NZ272143A (es) |
PL (1) | PL180481B1 (es) |
RU (1) | RU2152952C2 (es) |
ZA (1) | ZA953976B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL118974A (en) * | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
CZ304203B6 (cs) | 1999-04-30 | 2014-01-02 | Pfizer Products Inc. | Modulátor glukokortikoidního receptoru a léčivo pro léčbu zánětlivé choroby s jeho obsahem |
US7713989B2 (en) | 2000-04-27 | 2010-05-11 | Dow Robert L | Glucocorticoid receptor modulators |
DE60113032T2 (de) | 2000-10-30 | 2006-07-06 | Pfizer Products Inc., Groton | Glukokortikoidrezeptor-Modulatoren |
EP1285927A3 (de) | 2001-08-16 | 2005-06-29 | Schering Aktiengesellschaft | Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems |
US8193172B2 (en) | 2001-11-23 | 2012-06-05 | Pop Test Cortisol Llc | Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists |
US7250408B2 (en) | 2002-12-16 | 2007-07-31 | Bayer Schering Pharma Ag | Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility |
CA2517893C (fr) * | 2003-03-11 | 2012-05-15 | Trophos | Application a titre de medicaments de derives de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation |
CN107007581A (zh) | 2006-08-24 | 2017-08-04 | 田纳西大学研究基金会 | 取代的n‑酰基苯胺及其使用方法 |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
MX2015000572A (es) | 2012-07-13 | 2015-09-23 | Gtx Inc | Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms). |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
CA2977591A1 (en) | 2015-03-02 | 2016-09-09 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors |
CA2978960C (en) | 2015-03-30 | 2023-05-02 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
EP3335043B1 (en) | 2015-08-13 | 2021-03-31 | Corcept Therapeutics, Inc. | Method for differentially diagnosing acth-dependent cushing's syndrome |
CN105254697A (zh) * | 2015-11-17 | 2016-01-20 | 湖南成大生物科技有限公司 | △16甾体类化合物的制备方法 |
CA3011728A1 (en) | 2016-01-19 | 2017-07-27 | Corcept Therapeutics, Inc. | Differential diagnosis of ectopic cushing's syndrome |
EP3214092A1 (en) * | 2016-03-04 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one |
EP3641780A4 (en) | 2017-06-20 | 2021-02-24 | Corcept Therapeutics, Inc. | TREATMENT METHODS OF NEURO-EPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
CN114456223B (zh) * | 2022-01-24 | 2023-07-21 | 湖南科益新生物医药有限公司 | 3-缩酮的合成方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA8231B (en) * | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
FR2528434B1 (fr) * | 1982-06-11 | 1985-07-19 | Roussel Uclaf | Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament |
FR2639045B2 (fr) * | 1982-03-01 | 1994-07-29 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments |
FR2522328B1 (fr) * | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
EP0116974B1 (de) * | 1983-02-18 | 1986-10-29 | Schering Aktiengesellschaft | 11-Beta-Aryl-Estradiene, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate |
FR2549067B1 (fr) * | 1983-06-14 | 1985-12-27 | Roussel Uclaf | Derives estradieniques radioactifs marques au tritium, leur procede de preparation et leur application pour l'etude et le dosage radio-immunologique de steroides dans les fluides biologiques |
US4780461A (en) * | 1983-06-15 | 1988-10-25 | Schering Aktiengesellschaft | 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same |
DE3347126A1 (de) * | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
DE3410880A1 (de) * | 1984-03-21 | 1985-10-03 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 17-substituierte estradiene und estratriene |
DE3506785A1 (de) * | 1985-02-22 | 1986-08-28 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
DE3625315A1 (de) * | 1986-07-25 | 1988-01-28 | Schering Ag | 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate |
US4774236A (en) * | 1986-09-17 | 1988-09-27 | Research Triangle Institute | 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them |
EP0321010B1 (en) * | 1987-12-12 | 1993-02-03 | Akzo N.V. | New 11-arylsteroid compounds |
JP2785023B2 (ja) * | 1987-12-30 | 1998-08-13 | ルセル―ユクラフ | 17α位置を置換された17β―OH―19―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物 |
US4954490A (en) * | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
DE3822770A1 (de) * | 1988-07-01 | 1990-01-04 | Schering Ag | 13-alkyl-11ss-phenylgonane |
DE3832303A1 (de) * | 1988-09-20 | 1990-04-12 | Schering Ag | 11ss-phenyl-14ssh-steroide |
FR2643638B1 (fr) * | 1989-02-24 | 1991-06-14 | Roussel Uclaf | Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
FR2644789B1 (fr) * | 1989-03-22 | 1995-02-03 | Roussel Uclaf | Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
JP3135564B2 (ja) * | 1989-08-04 | 2001-02-19 | シエーリング アクチエンゲゼルシヤフト | 11β―置換16α,17α―メチレン―エストラ―4,9―ジエン―3―オン |
US5276023A (en) * | 1989-08-08 | 1994-01-04 | Roussel Uclaf | 19-nor-steroid esters |
FR2651435A1 (fr) * | 1989-09-07 | 1991-03-08 | Roussel Uclaf | Nouvelle utilisation de composes anti-progestomimetiques. |
US5407928A (en) * | 1990-08-15 | 1995-04-18 | Schering Aktiengesellschaft | 11β-aryl-gona-4,9-dien-3-ones |
AU687088B2 (en) * | 1993-08-04 | 1998-02-19 | Merck Sharp & Dohme B.V. | Antiglucocorticoid steroids for the treatment of anxiety disorders |
-
1995
- 1995-05-16 AT AT95201268T patent/ATE156836T1/de not_active IP Right Cessation
- 1995-05-16 CA CA002149496A patent/CA2149496C/en not_active Expired - Fee Related
- 1995-05-16 DK DK95201268.0T patent/DK0683172T3/da active
- 1995-05-16 ES ES95201268T patent/ES2106616T3/es not_active Expired - Lifetime
- 1995-05-16 ZA ZA953976A patent/ZA953976B/xx unknown
- 1995-05-16 DE DE69500542T patent/DE69500542T2/de not_active Expired - Fee Related
- 1995-05-16 EP EP95201268A patent/EP0683172B1/en not_active Expired - Lifetime
- 1995-05-17 NZ NZ272143A patent/NZ272143A/en unknown
- 1995-05-18 HU HU9501461A patent/HU217429B/hu not_active IP Right Cessation
- 1995-05-18 FI FI952424A patent/FI112491B/fi active
- 1995-05-18 KR KR1019950012374A patent/KR100359474B1/ko not_active IP Right Cessation
- 1995-05-18 JP JP12005195A patent/JP3814312B2/ja not_active Expired - Fee Related
- 1995-05-18 NO NO951968A patent/NO304379B1/no unknown
- 1995-05-18 AU AU20133/95A patent/AU701616B2/en not_active Ceased
- 1995-05-18 RU RU95107892/04A patent/RU2152952C2/ru not_active IP Right Cessation
- 1995-05-18 CN CN95105395A patent/CN1042539C/zh not_active Expired - Fee Related
- 1995-05-18 BR BR9502085A patent/BR9502085A/pt not_active IP Right Cessation
- 1995-05-18 PL PL95308666A patent/PL180481B1/pl not_active IP Right Cessation
- 1995-05-19 US US08/445,119 patent/US5620966A/en not_active Expired - Fee Related
-
1997
- 1997-10-30 GR GR970402861T patent/GR3025225T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
FI952424A (fi) | 1995-11-20 |
HUT71804A (en) | 1996-02-28 |
KR100359474B1 (ko) | 2003-03-12 |
CA2149496A1 (en) | 1995-11-20 |
HU9501461D0 (en) | 1995-06-28 |
BR9502085A (pt) | 1996-03-05 |
PL308666A1 (en) | 1995-11-27 |
CN1042539C (zh) | 1999-03-17 |
DK0683172T3 (da) | 1998-03-30 |
HU217429B (hu) | 2000-01-28 |
CN1126727A (zh) | 1996-07-17 |
JPH07316187A (ja) | 1995-12-05 |
RU95107892A (ru) | 1997-02-10 |
CA2149496C (en) | 2006-12-19 |
RU2152952C2 (ru) | 2000-07-20 |
DE69500542D1 (de) | 1997-09-18 |
PL180481B1 (pl) | 2001-02-28 |
EP0683172A1 (en) | 1995-11-22 |
FI112491B (fi) | 2003-12-15 |
NO951968D0 (no) | 1995-05-18 |
NZ272143A (en) | 1995-11-27 |
NO951968L (no) | 1995-11-20 |
AU701616B2 (en) | 1999-02-04 |
JP3814312B2 (ja) | 2006-08-30 |
ATE156836T1 (de) | 1997-08-15 |
ZA953976B (en) | 1996-01-19 |
DE69500542T2 (de) | 1998-01-02 |
US5620966A (en) | 1997-04-15 |
NO304379B1 (no) | 1998-12-07 |
GR3025225T3 (en) | 1998-02-27 |
FI952424A0 (fi) | 1995-05-18 |
KR950032267A (ko) | 1995-12-20 |
EP0683172B1 (en) | 1997-08-13 |
AU2013395A (en) | 1995-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2106616T3 (es) | Derivados de 11,21-bisfenilo-19-nor-pregnanos. | |
CA2107014A1 (en) | Therapeutic Agent for Parkinson's Disease | |
IL158459A0 (en) | Quinoline derivatives and quinazoline derivatives having azolyl group | |
ES2080297T3 (es) | Derivados 17-g(b)-sustituido-4-aza-5g(a)-androstan-3-ona y procedimiento de preparacion de estos. | |
GR3032083T3 (en) | Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone | |
TW427887B (en) | Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections | |
PT918776E (pt) | Sintese total de acilfulvenos antitumorais | |
SG48068A1 (en) | 7-(2-Aminoethyl)-benzothiazolones | |
DE69013959D1 (de) | Aminobenzolsulfonsäurederivate. | |
ATE223411T1 (de) | 1-methylcarbapenem-derivate | |
EP0785190A3 (es) | ||
ATE122892T1 (de) | Zusammensetzung gegen katarakt. | |
TW275629B (es) | ||
ES8705363A1 (es) | Un procedimiento para preparar derivados de tetrahidronaftaleno |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 683172 Country of ref document: ES |